Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 06, 2026 07:00 ET | Source: Immutrin

Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary

Former Edgewise and Merck leader brings more than 15 years’ experience to guide Immutrin’s clinical strategy as the Company advances towards first-in-human studies Cambridge, UK, 6th May 2026Immutrin...
May 06, 2026 02:00 ET | Source: Immutrin

Immutrin appoints leading cardiovascular drug development expert Dr. Robert Blaustein as Chief Medical Officer and establishes US subsidiary

Former Edgewise and Merck leader brings more than 15 years’ experience to guide Immutrin’s clinical strategy as the Company advances towards first-in-human studies Cambridge, UK, 6th May 2026Immutrin...
March 24, 2026 08:00 ET | Source: Immutrin

Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis

Oversubscribed financing led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise...
March 24, 2026 03:00 ET | Source: Immutrin

Immutrin raises £65 million ($87 million) Series A to develop next generation antibody therapy for ATTR amyloidosis

Oversubscribed financing led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise...